Drug Discovery and Development Division, Patanjali Research Institute, NH-58, Haridwar, 249405, Uttarakhand, India; Department of Allied and Applied Sciences, University of Patanjali, Patanjali Yog Peeth, Roorkee-Haridwar Road, Haridwar, 249 405, Uttarakhand, India.
Drug Discovery and Development Division, Patanjali Research Institute, NH-58, Haridwar, 249405, Uttarakhand, India.
Biomed Pharmacother. 2020 Jun;126:110063. doi: 10.1016/j.biopha.2020.110063. Epub 2020 Mar 4.
Asthma is a chronic allergic respiratory disease with limited therapeutic options. Here we validated the potential anti-inflammatory, anti-asthmatic and immunomodulatory therapeutic properties of calcio-herbal ayurvedic formulation, Divya-Swasari-Ras (DSR) in-vivo, using mouse model of ovalbumin (OVA) induced allergic asthma. HPLC analysis identified the presence of various bioactive indicating molecules and ICP-OES recognized the presence of Ca mineral in the DSR formulation. Here we show that DSR treatment significantly reduced cardinal features of allergic asthma including inflammatory cell accumulation, specifically lymphocytes and eosinophils in the Broncho-Alveolar Lavage (BAL) fluids, airway inflammation, airway remodelling, and pro-inflammatory molecules expression. Conversely, number of macrophages recoverable by BAL were increased upon DSR treatment. Histology analysis of mice lungs revealed that DSR attenuates inflammatory cell infiltration in lungs and thickening of bronchial epithelium. PAS staining confirmed the decrease in OVA-induced mucus secretion at the mucosal epithelium; and trichrome staining confirmed the decrease in peribronchial collagen deposition upon DSR treatment. DSR reduced the OVA-induced pro-inflammatory cytokines (IL-6, IL-1β and TNF-α) levels in BALF and whole lung steady state mRNA levels (IL-4, -5, -33, IFN-γ, IL-6 and IL-1β). Biochemical assays for markers of oxidative stress and antioxidant defence mechanism confirmed that DSR increases the activity of SOD, Catalase, GPx, GSH, GSH/GSSG ratio and decreases the levels of MDA activity, GSSG, EPO and Nitrite levels in whole lungs. Collectively, present study suggests that, DSR effectively protects against allergic airway inflammation and possess potential therapeutic option for allergic asthma management.
哮喘是一种慢性过敏性呼吸道疾病,治疗选择有限。在这里,我们使用卵清蛋白(OVA)诱导的过敏性哮喘小鼠模型,体内验证了钙草药阿育吠陀配方 Divya-Swasari-Ras(DSR)的潜在抗炎、抗哮喘和免疫调节治疗特性。HPLC 分析确定了存在各种生物活性指示分子,ICP-OES 识别出 DSR 配方中 Ca 矿物质的存在。在这里,我们表明 DSR 治疗可显著减轻过敏性哮喘的主要特征,包括支气管肺泡灌洗液(BAL)中炎症细胞的积累,特别是淋巴细胞和嗜酸性粒细胞,气道炎症,气道重塑和促炎分子的表达。相反,DSR 治疗后可增加 BAL 中可回收的巨噬细胞数量。对小鼠肺部的组织学分析表明,DSR 可减轻肺部炎症细胞浸润和支气管上皮增厚。PAS 染色证实 DSR 可减少 OVA 诱导的粘膜上皮中粘液分泌;三原色染色证实 DSR 可减少周围支气管胶原沉积。DSR 降低了 BALF 和整个肺稳态 mRNA 水平(IL-4、-5、-33、IFN-γ、IL-6 和 IL-1β)中 OVA 诱导的促炎细胞因子(IL-6、IL-1β 和 TNF-α)水平。用于氧化应激和抗氧化防御机制标志物的生化测定证实,DSR 增加了整个肺部的 SOD、过氧化氢酶、GPx、GSH、GSH/GSSG 比值的活性,并降低了 MDA 活性、GSSG、EPO 和亚硝酸盐水平。综上所述,本研究表明,DSR 可有效预防过敏性气道炎症,并为过敏性哮喘的治疗提供潜在的治疗选择。